Lv1
66 积分 2026-02-03 加入
Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs
1个月前
已完结
YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer
1个月前
已完结
Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate Cancer
3个月前
已关闭
Abstract PS1-10-08: Er riptacs drive tumor selective cell death in post-cdk4/6i resistance settings and demonstrate oral efficacy in cdx and pdx models
5个月前
已关闭
Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate
6个月前
已完结
Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives
6个月前
已完结
Discovery of N-(1-(6-Oxo-1,6-dihydropyrimidine)-pyrazole) Acetamide Derivatives as Novel Noncovalent DprE1 Inhibitors against Mycobacterium tuberculosis
7个月前
已完结
Peptide design through binding interface mimicry with PepMimic
7个月前
已完结
皖公网安备34019202002308
